Review of regulatory T cell therapy in solid organ transplantation with no reported outcomes

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published May 8, 2026 Medically reviewed May 8, 2026 Study authors: Jie Yang, Xusheng Zeng, Ke Jiang, Xiangli Pang, Ai Huang DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note that this review lacks reported outcomes for regulatory T cell therapy in solid organ transplantation.

This publication is a narrative review focusing on regulatory T cell therapy within the context of solid organ transplantation. The scope of the article addresses the potential role of this intervention in this specific patient population. However, the source document does not provide a defined population, sample size, or specific setting for the discussion.

The authors synthesize the current landscape of regulatory T cell therapy but explicitly state that primary outcomes and secondary outcomes were not reported. Furthermore, details regarding adverse events, tolerability, and discontinuations are absent from the provided information. The review does not present pooled effect sizes or quantitative data because the underlying trial-level details are missing.

Limitations acknowledged by the authors include the lack of reported data on safety and efficacy. The review does not establish causality or provide a certainty note regarding the intervention. Given the absence of specific results, the practice relevance remains unclear, and clinicians cannot rely on this source for quantitative guidance on dosing or expected benefits.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

The long-term outcomes of solid organ transplantation are constrained by alloimmune rejection and the toxicities of lifelong immunosuppression; durable tolerance therefore remains an unmet goal. Regulatory T cells are central mediators of peripheral tolerance, capable of restraining cellular and antibody-mediated rejection while shaping the intragraft inflammatory and repair milieu, supporting a mechanistic rationale for immunosuppression minimization. This review integrates key mechanisms by which Tregs regulate transplant immunity and summarizes evidence for Treg-directed interventions from preclinical studies to early clinical translation across liver, kidney, heart, and lung transplantation. To address the persistent gap between biological promise and inconsistent clinical efficacy, we organize translational barriers using a failure-mode perspective across the therapeutic continuum, encompassing product attributes and manufacturing quality, in vivo delivery and persistence, phenotypic stability under inflammatory stress, target engagement, and endpoint sensitivity. In addition, we outline a biomarker-driven evaluation approach centered on quantifiable proof-of-biology and clinically meaningful surrogate endpoints to enable patient stratification, dose/regimen optimization, and risk-controlled immunosuppression minimization. Together, advances in precision engineering, harmonized CMC standards, and mechanism-linked immune monitoring may facilitate reproducible and verifiable tolerance-oriented immunotherapies in solid organ transplantation.